Editor's Spotlight: Video Diary

WATCH: Regulatory scrutiny places emphasis on probiotic mechanisms of action

This content item was originally published on www.nutraingredients.com, a William Reed online publication.

By Will Chu

- Last updated on GMT

Do we need to know a probiotic’s mechanism of action? It’s a question posed by DuPont Nutrition and Health’s Dr Arthur Ouwehand as he took to the stage at Probiota.

Presenting to delegates in Copenhagen, Dr Ouwehand, a technical fellow and research manager at the firm, argued that for some in the industry as long as it works, that’s all that matters.

But as a scientist Dr Ouwehand points to previous work, where the assumption was that there was a good understanding of how probiotics work.

“That is not the case,”​ he explains. “Scientists can make hypotheses, propose mechanisms but the real proof seems to be lacking.

“The main issue is does the mechanism need to be known? Scientists will say ‘yes’ because it’s interesting but that’s not good enough. You could argue that as long as it works, we are happy.

Looking ahead, Dr Ouwehand points to a need to know in order to create different probiotic combinations, combining them with other components that affect the mechanisms in different ways.

Regulatory speaking, the mechanisms particularly resonate with agencies such as The European Food and Safety Authority (EFSA), who are scrutinising probiotic science much more intensely in a response to their increasing popularity.

Lactose intolerance

Dr Arthur Ouwehand
Dr Arthur Ouwehand, Technical Fellow and Research Manager, Global Health & Nutrition Sciences, DuPont Nutrition & Health. ©ArthurOuwehand

Dr Ouwehand’s presentation entitled ‘Mechanisms of probiotic action: Driving the development for reliable health benefits for probiotics,’​ looks toward the future in which he would like to see the selection of more effective probiotic strains and the optimisation of probiotic product manufacturing and quality assurance.

He also mentions the need to drive the improved design of probiotic formulation, and support the design of effective clinical trials with the best chance of realising benefits to human health.

“In the future, when we understand the general mechanisms, we may be able to say a person’s genetic make-up or microbiota may determine a certain probiotic mechanism of action and associated risk of disease,”​ he said.

“So how can we optimise that both in research and the targeting of consumers that would benefit the most? But that is further down the road.”

Related news

Show more

Related products

show more

HRB probiotics in the HMO era

HRB probiotics in the HMO era

Content provided by Morinaga Milk Industry Co., Ltd. | 29-Apr-2024 | White Paper

Discover the science behind human-residential bifidobacteria (HRB) probiotics and their superior benefits for infants.

Vitafoods Europe highlight: Fucoidan

Vitafoods Europe highlight: Fucoidan

Content provided by Marinova Pty Ltd | 08-Apr-2024 | Infographic

Fucoidans are bioactive compounds found naturally in brown seaweeds. Maritech® fucoidans are the world’s only high purity, certified organic fucoidans...

Related suppliers

Follow us


View more